Eil Lilly announces Zepbound to be sold directly to consumers

(4:4)

Eli Lilly CEO David Ricks: Projecting 32% total growth for company in 2025

(6:33)

The David Rubenstein Show: Eli Lilly CEO Dave Ricks

(24:7)

Eli Lilly climbs after earnings, top analyst talks what's next for pharma giant

(5:9)

Eli Lilly: Becoming the world's biggest pharmaceutical company 1876-2024

(2:1econd)

Eli Lilly Now Selling Zepbound Vials at 50% Discount

(27)

Eli Lilly to sell Zepbound directly to consumers without insurance coverage

(3:14)

Inside Lilly's Corporate Center

(3:40)

David A Ricks, Chair and Chief Executive Officer of Eli Lilly and Company

(45:30)

Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz

(2:53)

Eli Lilly CEO on Fighting Cancer and Obesity, Drug Pricing

(9:25)

Why Work at Eli Lilly and Company?

(1:21)

Eli Lilly posts mixed quarter even as demand for weight loss, diabetes drugs soars

(1:4)

Cramer’s Mad Dash: Eli Lilly

(2:19)

Eli Lilly CEO: We have 11 pipeline projects in obesity

(2:22)

Pfizer is 'deeply sorry'

(13:46)

Sanofi CEO on AI's Impact, Lung Disease Drug Clearance

(8:54)

Bloomberg Turnaround: AstraZeneca

(24:7)

Eli Lilly's drop after earnings is a buying opportunity, says Mizuho's Jared Holz

(5:27)

Buy the weakness in Eli Lilly, says Mizuho Healthcare Strategist Jared Holz

(5:48)

Lilly's profit forecast brings relief amid Zepbound miss | REUTERS

(1:5)